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We studied the expression of the core region of the hepatitis B virus genome in mammalian cells with
recombinant plasmid vectors. Stably transformed rat fibroblast cell lines were established by transfection with
vectors containing subgenomic and genome-length hepatitis B virus DNA, followed by G418 selection. The
RNA transcripts directed by the core region were characterized by Northern blot hybridization and Si nuclease
mapping. Using the chloramphenicol acetyltransferase gene expression system, the promoter activity located
upstream of the core open reading frame was confirmed. The synthesis of core and e polypeptides was studied
with a commercial radioimmunoassay. These studies show that partial deletion of the precore sequences
abolished secretion of the e antigen, but there was pronounced synthesis of the core antigen in transfected cells.
The sequence analysis of cloned hepatitis B virus (HBV)
DNA has resulted in the identification of at least four open
reading frames (ORFs): S/pre-S, C, X, and P (21, 32). The S
gene has been efficiently expressed in cultured cells (5, 23,
24, 27), and the transcriptional control elements have been
defined (5, 23a, 27). Expression of the core (C) region with
native transcriptional control elements, however, has
proven to be more difficult, probably reflecting the strict host
and tissue tropism of the virus. Recent studies have indi-
cated that the promoter preceding the C ORF is dependent
on a highly specific upstream enhancer sequence which is
active only in human hepatocytes (14).
The C ORF contains an in-frame ATG located 87 base
pairs (bp) downstream of the first ATG of this ORF. The C
region is responsible for the expression of polypeptides with
distinct antigenic determinants designated core (HBcAg) and
e (HBeAg) (19). Both of these antigens are found associated
with the icosahedral core of the viral particle (28) derived
from intact virions and infected hepatocytes; HBeAg is also
found in the serum of infected individuals (16). Takahashi et
al. (29) have shown that HBeAg from the serum of chronic
carriers and HBcAg from virions react with anti-HBe or
anti-HBc, respectively, in their native conformations, but
share antigenicity in their denatured forms.
Studies on the expression of the C ORF have used
recombinant vectors employing heterologous control ele-
ments such as the simian virus 40 promoters (34) or have
relied on in vitro transcription (7, 20) to determine the basic
structure of C ORF transcripts. The in vitro studies have
indicated that the 5' end of the C ORF-specific RNA maps at
about nucleotide (nt) 1689 (20), located about 130 bp up-
stream from the first ATG (nt 1820). Other studies have
shown greater-than-genome-length RNA species, both in
transfection with a head-to-tail multimer of the HBV genome
(10) and in animals infected with HBV and related viruses (4,
6, 9). It has been suggested that this large RNA species could
serve as a message for the C region. A 1.8-kilobase (kb)
subgenomic fragment of HBV, however, has been shown to
direct the synthesis of C ORF-related polypeptides (36).
In the present study we initially focused on the in vivo
expression of the C ORF in stably transformed rat cell lines,
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directed by genomic and subgenomic fragments containing
native transcriptional control elements. We examined the C
ORF-related mRNA species from cloned cell lines, which
express and secrete HBeAg into the culture medium. We
also demonstrated the promoter activity of the region up-
stream of the C ORF by using the easily assayable chloram-
phenicol acetyltransferase (CAT) gene and by S1 nuclease
mapping of the CAT mRNA. Identification of the HBV
enhancer, which appears to be functionally active in human
liver cells (14, 22), led us to transiently express the C ORF in
a human hepatoma cell line. These studies demonstrate that
the entire C ORF under the influence of native transcrip-
tional control elements directs the synthesis and secretion of
only HBeAg. By deleting the first ATG and flanking se-
quences, also called the precore region, detectable secretion
of HBeAg is abolished, but the antigen is found
intracellularly. Transfection with this construct also resulted
in the synthesis of large amounts of HBcAg.
MATERIALS AND METHODS
Construction of plasmid vectors. Recombinant vectors were
constructed from a cloned subtype adw HBV genome
described previously (25). Plasmids pML and pMLneo were
obtained from M. Botchan (University of California,
Berkeley), and plasmid pSV2CAT was from B. Howard
(National Institutes of Health, Washington, D.C.). All
enzymes were obtained either from Boehringer Mannheim
Biochemicals (Indianapolis, Ind.) or New England BioLabs,
Inc. (Beverly, Mass.). For construction of pNEC (Fig. 1A),
HBV DNA was digested to completion with restriction
enzyme BamHI, and the termini were blunted with T4 DNA
polymerase. The 1.8-kb fragment, containing the entire C
ORF with 400 bp of upstream sequences and 800 bp of
downstream sequences, was purified. After EcoRI linkers
were added, the fragment was ligated with EcoRI-digested
pMLneo by standard methods (17). Plasmid pNER (Fig. 1A)
was constructed in a similar manner, with HBV DNA
linearized with EcoRI.
For the construction of pCEN (Fig. 1B), HBV DNA was
digested with HpaI and EcoRI, and the 2.3-kb fragment was
isolated and cloned into pML between the ClaI (blunted with
T4 DNA polymerase) and EcoRI restriction sites. Plasmid
pSCAPC (Fig. 1B) contained HBV sequences similar to
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FIG. 1. Construction of recombinant plasmid vectors. (A) pNEC and pNER construction. (B) Schematic representation of HBV
sequences in pCEN and pSCAPC. The sequences between the MstI and RsaI sites have been deleted in pSCAPC. Pre-S, S, pre-C, and C refer
to the ORFs of HBV. Abbreviations used: A, AccI; B, BamHI; R, EcoRI; Hh, HhaI; Hp, HpaI; M, MstI; Rs, RsaI; S, SstII; T, TaqI; Al.
Ph., calf alkaline phosphatase; Cp, C promoter; En, enhancer sequences.
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those of pCEN except with a deletion of the sequences
between restriction sites MstI (nt 1806) and RsaI (nt 1856).
This resulted in the removal of the first ATG at map position
1820 and about 50 flanking nucleotides.
The two HBV fragments used to assay for C promoter
activity were inserted between the AccI and HindIII sites of
the promoterless plasmid pSVOCAT (11) by blunt-end liga-
tions, using T4 DNA polymerase and T4 DNA ligase (see
Fig. 3A). The HBV fragment in pCPCAT contained nucleo-
tide sequences from map positions 1076 (AccI) to 1991
(BglII) and included both the ATGs in the C ORF. The HBV
fragment in pCMCAT, from nt 1076 (AccI) to 1806 (MstI),
lacked the two ATGs and downstream sequences. Both
fragments however, contained the HBV enhancer element
(14, 22). Plasmid pCPCAT-AE (see Fig. 3A) was generated
by removal of the HBV enhancer element (AccI to SstII, nt
1076 to 1458) from pCPCAT. CAT activity was assayed at 48
h posttransfection by the method of Gorman et al. (11).
Transfection and establishment of cell lines. Rat fibroblast
cells (R. Erikson, Harvard University, Cambridge, Mass.)
were transfected, and permanent cell lines were established
by G418 selection according to methods described previ-
ously (12, 26). Clones resistant to G418 were screened by
RNA dot-blot analysis for the expression of C-specific RNA.
NEC-4 is a cell line established by pNEC transfection, and
NER-41 was established with pNER. For transient expres-
sion in Hep-G2 cells (kind gift of B. Knowles, Wistar
Institute, Philadelphia, Pa. [14]), 2 pmol of plasmid DNA
was used to transfect (12). Plasmid pBR322 DNA was used
to keep the DNA concentration constant at 12 Rg/100-mm
dish. Cells were transfected at about 60% confluency (5 x
106 to 7 x 106 cells per dish), with a transfection efficiency of
10 to 16%.
Analysis of poly(A)+ RNA. Cytoplasmic RNA was isolated
by a modification of the method of Chirgwin et al. (8).
Confluent cells from tissue culture dishes were scraped off
and lysed in Nonidet P-40 lysis buffer (10 mM Tris, 1 mM
MgCl2, 100 mM NaCl, 0.5% Nonidet P-40). Nuclei were
removed by centrifugation, and the cleared lysates were
mixed with 6 M guanidine isothiocyanate. The mixture was
pelleted through a 1.2-ml cushion of 5.7 M CsCl by centrif-
ugation in an SW-55 rotor (Beckman Instruments, Inc.,
Fullerton, Calif.) at 44,000 rpm for 18 h. RNA pellets were
suspended in STE (0.1 M NaCl, 0.5 M Tris [pH 7.5], 1 mM
EDTA) and precipitated with ethanol. Poly(A)+ RNA was
purified by chromatography through an oligo(dT)-cellulose
column (1). For Northern blot hybridization (30), 20 ,ug of
poly(A)+ RNA was subjected to electrophoresis through a
1% agarose-formaldehyde gel (17). The blotted RNA was
hybridized with a 1-kb (nt 1806 to 2812) radiolabeled nega-
tive-strand RNA generated in vitro by the SP6 system (18).
S1 nuclease mapping was by the methods of Weaver and
Weissman (32). The 5'-end-labeled probe used in S1 mapping
of the C ORF-specific transcripts contained HBV DNA
sequences from nt 1406 to nt 2020 (BamHI to TaqI).
Analysis of HBcAg and HBeAg. Culture supernatants (8
ml/100-mm dish) were collected 48 h posttransfection for
transient expression assays and at cell confluency for per-
manent cell lines. They were then clarified at 12,000 x g for
30 min and concentrated 35- to 40-fold with an Amicon YM2
filter. Samples (200 ,lI) of concentrated material were used
for radioimmunoassay (HBe RIA; Abbott Laboratories,
North Chicago, Ill.). Culture medium from a stable cell line,
NET 22 (23a), which does not contain an intact C ORF was
used as a control. To assay the cell lysates, confluent cells in
100-mm tissue culture plates were harvested, and the cells
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FIG. 2. Characterization of C-region transcripts. (A) Northern
blot hybridization of poly(A)+ RNA (20 p.g) from cell lines NER-41
(lane 1) and NEC-4 (lane 2). Transcripts generated in vitro by the
SP6 system were used as molecular weight standards. A 1-kb (nt
1806 to 2812) SP6 radiolabeled negative-strand RNA was used as a
probe. (B) Si nuclease mapping analysis of poly(A)+ RNA from
NEC-4 (lane 2) and NER-41 (lane 3). NEC-4 or NER-41 poly(A)+
RNA (5 p.g) was hybridized with the probe shown in panel C.
Molecular weight standards in lane 1 are from end-labeled Hinfl-
digested pBR322 DNA. (C) Schematic representation of Sl nuclease
analysis. Abbreviations used: B, BamHI; R, EcoRI; T, TaqI.
were lysed by sonication for two 5-s bursts in a Branson cell
disruptor 185 at maximum output. To distinguish between
HBeAg and HBcAg, we used purified human anti-core
immunoglobulin fraction which was free from HBeAg and
anti-HBe reactivity (see Table 2) to block Abbott HBe RIA
activity. After antigen binding according to the directions
included with the kit, an additional incubation with anti-HBc
was included. Reduction in the positive/negative (P/N) value
in the anti-HBc blocking assay indicated the presence of
HBcAg; no reduction indicated the absence of HBcAg. All
assays were done in a 200-,ul volume and represent medium
or lysate from one 100-mm dish.
RESULTS
Analysis of C gene-related transcripts. Northern blot anal-
ysis (Fig. 2A) of poly(A)+ RNA from NEC-4 and NER-41
cell lines revealed a band with a migration pattern consistent
with a size of about 1.1 kb. This band probably contained
more than one species of RNA transcripts. At least 20 ,ug of
poly(A)+ RNA and 1 week of exposure were required to
visualize this band, indicating the low abundance of the
mRNA species. The sizes of the RNAs were assessed by
using RNA species of various molecular sizes, generated in
vitro by the SP6 system (18), as markers.
We used Si nuclease analysis to map the initiation sites of
the C ORF transcripts. Poly(A)+ RNA from NEC-4 or
I
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FIG. 3. Analysis of C promoter-enhancer-directed expression. (A) Construction of CAT plasmids. Solid bars represent HBV DNA
sequences which were inserted into pSVOCAT at the AccI and HindIII sites. (B) Si nuclease analysis ofRNA transcripts from pCMCAT (lane
1)- or pCPCAT (lane 2)-transfected Hep-G2 cells. Poly(A)+ RNA (1.5 ,tg) from pCMCAT or pCPCAT was hybridized with the appropriate
probes described in the text. Molecular weight markers were 5'-end-labeled fragments from a Hinfl digestion of pBR322. (C) Schematic
representation of S1 nuclease analysis. (D) Expression of CAT activity in HeLa cells (lanes 1 to 3) and Hep-G2 cells (lanes 4 to 6) owing to
plasmids pCMCAT (lanes 1 and 4), pCPCAT (lanes 2 and 5), and pCPCAT-AE (lanes 3 and 6). Lane 7 is a positive control with CAT enzyme.
Each assay included extract equivalent to 0.5 mg of protein and was carried out for 2 h. After separation of chloramphenicol (cm) and its
acetylated forms, 1-acetate (a) and 3-acetate (b), by thin-layer chromatography (0.2-mm silica), the percent acetylation (%Ac) was determined
by scintillation counting. Abbreviations used are: A, AccI; B, BamHI; H, HindIII; M, MstI; Bg, Bglll; S, SstII; Cp, C promoter; En, enhancer
sequences.
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NER-41 cells was annealed with a 5'-end-labeled DNA
fragment (BamHI to TaqI, nt 1406 to 2020; Fig. 2C). S1-
protected fragments were fractionated through a 6%
urea-polyacrylamide gel (Fig. 2B). A major S1-protected
band of about 230 nt was seen which corresponded with a 5'
end at nt 1790 on the HBV map. Two additional less
abundant S1-protected fragments of about 190 and 100 nt,
corresponding to nt 1830 and 1920 on the HBV map, were
also resolved on the gel, RNA from the NER-41 cell line
contained an additional band not seen in the NEC-4 RNA.
This corresponded to an RNA initiation site at about nt 1870
(150-bp band). It is clear from these results that at least one
species of C-specific RNA does not include the first ATG at
nt 1820 and that the C ORF RNA transcripts seem to be
heterogeneous, similar to other HBV and related virus
transcripts (9, 23a, 30).
Assay for core promoter by CAT expression. The expres-
sion of the C ORF by our recombinant vectors is controlled
by the native promoter sequences as shown by S1 nuclease
mapping data (Fig. 2B). To independently test the promoter
activity in sequences upstream of the C ORF, we utilized the
bacterial CAT gene system. Construction of the CAT plas-
mids is discussed in Materials and Methods. Plasmid
pCPCAT showed about 60% acetylation of chloramphenicol
in Hep-G2 cells (Fig. 3D, lane 5), a human hepatoma cell line
negative for HBV sequences (14). This activity was mark-
edly reduced when assayed under identical conditions in
HeLa cells (Fig. 3D, lane 2) or several other nonhepatic or
nonhuman (or both) cell lines (14). Plasmid pCPCAT-AE
(Fig. 3A), in which the upstream enhancer sequences were
deleted, was also unable to efficiently express CAT activity
in Hep-G2 cells (Fig. 3D, lane 6), indicating the dependence
of the core promoter on the enhancer sequences.
Plasmid pCPCAT contains HBV sequences bound by the
restriction sites AccI (nt 1076) and BglII (nt 1991). This
includes the two ATGs as well as about 85 bp of the C ORF.
In view of the model for eucaryotic systems that the first
ATG is preferentially used for translational initiation (15),
we felt that the two C ORF ATGs in addition to the ATG of
the CAT gene in pCPCAT might be interfering with CAT
expression. We therefore constructed plasmid pCMCAT
(Fig. 3A) containing an HBV fragment bound by the restric-
tion sites AccI (nt 1076) and MstI (nt 1806), removing the two
TABLE 1. HBcAg and HBeAg synthesis in stably transformed
rat cell lines'
Cells Source Anti-HBc' P/Nc
NEC-4 Medium - 5.8 ± 0.5
NEC-4 Medium + 5.7 ± 0.3
NER-41 Medium - 7.1 ± 0.6
NER-41 Medium + 7.3 ± 0.2
NEC-4 Lysate - 2.3 ± 0.6
NEC-4 Lysate + 2.3 ± 0.5
NER-41 Lysate - 4.0 ± 1.6
NER-41 Lysate + 3.4 ± 0.6
a Assayed by Abbott HBe RIA.
b +, Additional incubation with anti-HBc (see Table 2) before incubation
with 251I-labeled antibody; -, no anti-HBc used.
C P/N, Positive/negative. Negative values were obtained with a cell line
which does not contain an intact C gene. A P/N greater than 2 is considered
positive. All values are normalized to a positive control and represent two
values.
TABLE 2. Analysis of human anti-HBca
Testb Sample N/Pc P/Nd
CORAB +Controle 44.7
CORAB Anti-HBc 67.3
Anti-HBe +Control 3.6
Anti-HBe Anti-HBc 0.28
HBe RIA +Control 3.7
HBe RIA Anti-HBc 1.1
a Gamma globulin fraction of human sera positive for anti-HBc.
bAll tests were performed with the indicated kits from Abbott Labora-
tories.
I Antibody assays are expressed as negative over positive. Negative control
in all cases was normal human serum. For the CORAB assay, an N/P value
greater than 5 is considered positive. For anti-HBe, an N/P value greater than
2 is considered positive.
d Antigen assays are expressed as positive over negative. A P/N value
greater than 2 is considered positive.
' All positive controls are positive human serum samples provided with
Abbott kits.
ATGs as well as other C ORF sequences while retaining the
promoter and enhancer region. Surprisingly, pCMCAT was
unable to efficiently express CAT activity in Hep-G2 cells
(Fig. 3D, lane 4). This suggests that sequences downstream
of the MstI site (nt 1806) contain important regulatory
signals.
We further carried out Si nuclease mapping of CAT RNA
transcribed from pCPCAT and pCMCAT (Fig. 3B and C). A
5'-end-labeled probe was generated from the respective
plasmids by digestion with SstII (HBV nt 1458) and EcoRI
(230 bp 3' to the CAT gene ATG). The probes contained
either 540 bp (pCPCAT) or 351 bp (pCMCAT) of HBV
sequences and 250 bp of CAT gene sequences. Poly(A)+
RNA from Hep-G2 cells transiently transfected with
pCPCAT or pCMCAT was annealed with the respective
probes. pCPCAT produced CAT transcripts whose initiation
sites mapped at two positions upstream of the C ORF region
(Fig. 3B, lane 2). The smaller S1-protected fragment (about
350 nt) places the initiation site at about map position 1890
on the HBV map, between the two ATGs. The larger
S1-protected fragment (about 600 nt) corresponds to an RNA
start site at approximately 1640 on the HBV map, upstream
of the two ATGs. An RNA start site in this region has been
described earlier in an in vitro transcription study (20). The
absence of an S1-protected fragment in pCMCAT-
transfected cells (Fig. 3B, lane 1) further suggests that
important regulatory signals were deleted in this construct.
The low level of CAT activity seen in the CAT assay in
pCMCAT-transfected Hep-G2 cells (Fig. 3D, lane 4), even
though no mRNA was detectable, is probably due to the
greater sensitivity of detection of the CAT assay, as com-
pared with S1 nuclease analysis, or the instability of CAT
mRNA (S. Jameel, unpublished data), or both.
Analysis of antigen production from stably transformed cell
lines. The NEC-4 and NER-41 cell lines were further ana-
lyzed for the production of the core and e antigens (Table 1).
The clarified culture supernatants were concentrated 35- to
40-fold with an Amicon YM2 filter and assayed for HBeAg-
HBcAg reactivity with a commercial RIA kit (Abbott Lab-
oratories). Since the Abbott RIA kit used to assay for
HBeAg utilizes human anti-HBe, which is always found in
conjunction with anti-HBc, this system detects HBcAg as
well as HBeAg (34). To distinguish between the core and e
polypeptides produced in our cell lines, we utilized human
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TABLE 3. Effect of enhancer on HBeAg synthesis during
transient expression in Hep-G2 cellsa
Plasmid P/Nb
pCEN.. 8.6
pNEC 1.2
pNER.. 3.3
a See Table 1, footnote a. Assays were done with concentrated culture
media.
b P/N, Positive/negative. Negative control was untransfected Hep-G2 cells.
A P/N value greater than 2 is considered positive.
anti-HBc in a blocking assay. The anti-HBc was analyzed by
several commercial RIA kits from Abbott Laboratories: the
CORAB assay detects anti-HBc, the HBe RIA detects
HBeAg and HBcAg, and the anti-HBe detects antibody to
HBeAg. The results of this analysis (Table 2) clearly show
that the anti-HBc antibody is free of anti-HBe and HBeAg.
By blocking with anti-HBc we showed that the
polypeptides secreted into the culture supernatants of the
NEC-4 and NER-41 cell lines bear only e antigenic determi-
nants (Table 1); we could not detect any HBcAg in the
concentrated culture supernatants. Detectable levels of
HBeAg were also found in the cell lysates, but no HBcAg
was detected (Table 1). These results, taken together, indi-
cate that the predominant C ORF protein product in these
cells and in the culture supematants is HBeAg.
Effect of enhancer sequences on HBe-HBcAg production.
Recent studies by Jameel and Siddiqui (13) clearly demon-
strate that the HBV enhancer element is necessary to
regulate transcription from the putative core promoter.
Since the enhancer element exhibits tissue and host tropism,
i.e., it is functionally active only in human cells of hepatic
origin, we studied the transient expression of the C ORF in
the human hepatoma cell line Hep-G2 under the control of
the native regulatory elements. Plasmids pNEC, pNER, and
pCEN (Fig. 1) were used for the transient expression of
HBeAg-HBcAg in Hep-G2 cells. Culture medium was as-
sayed as described above, and the results are described in
Table 3. Transient expression of pCEN, which contains the
enhancer element and core promoter region, led to the
synthesis of levels of e antigen easily detectable by our
assay. Cells transfected with pNEC, which does not contain
the enhancer sequences, did not produce detectable levels of
antigen. Transfection of Hep-G2 cells with pNER, which
also produces HBsAg (data not shown), showed a marked
reduction in the expression of HBeAg-HBcAg as compared
with that of pCEN-transfected cells. This may reflect a
regulatory control exerted by HBsAg on HBeAg-HBcAg
synthesis.
Deletion of precore sequences of the C ORF. The first ATG
of the C ORF, at map position 1820, is followed by an
in-frame ATG located about 87 bp downstream. To deter-
mine how the precore sequences (bound by the two ATGs)
affect synthesis of the HBcAg and the HBeAg polypeptides,
plasmid pSCAPC was constructed, in which precore se-
quences upstream of the second ATG were deleted, while
the core promoter region and enhancer element were re-
tained (Fig. 1B). We then transiently expressed pCEN and
pSCAPC in Hep-G2 cells and assayed for HBeAg and
HBcAg as described above (Table 4). In each assay the
lysate or the concentrated culture medium equivalent to one
100-mm dish (approximately 107 cells) was used.
The culture medium of the pCEN-transfected Hep-G2
cells contained HBeAg, as it was not significantly blocked
with anti-HBc (Table 4). Much less antigen was seen in the
cell lysate, indicating that the protein is secreted and that its
accumulation in the medium is not due to cell lysis. Trans-
fection of Hep-G2 cells with pSCAPC resulted in the accu-
mulation of comparatively large amounts of antigen in the
culture medium as detected by RIA (Table 4). However, the
immunoreactivity of this sample was completely blocked by
the addition of anti-HBc, indicating that all of the antigen is
HBcAg. In the lysate of these cells anti-HBc reduced the
P/N value of the RIA by about 60%, suggesting that both
core and e antigenic polypeptides are found within the cells.
In the assay of the pSCAPC-transfected cells, the P/N values
for the culture medium and the cell lysate were approxi-
mately the same, suggesting that secretion is not taking place
but that cell lysis is occurring and releasing antigen into the
culture medium. A lactic dehydrogenase assay (35) of me-
dium from transfected cells indicated that about 10% of the
cells were lysing as compared with untransfected cells (M.
Roossinck, unpublished data).
It should also be noted that HBeAg is not found in the
culture medium of pSCA&PC-transfected cells but only in the
cell lysate. This may reflect a membrane association of
HBeAg within the cells, which would pellet with the cell
debris in the clarified medium used for the assay. We
obtained similar results in a transiently replicating system
with COS cells transfected with appropriate plasmids (un-
published data). We can conclusively say from these results
that the deletion of the first ATG of the C ORF abolishes
secretion of HBeAg in Hep-G2 cells and greatly augments
the synthesis of HBcAg. This increase in HBcAg synthesis
suggests a regulatory repression of HBcAg synthesis when
the entire sequence of the C region is available.
DISCUSSION
The studies described here dealt with the expression of the
HBV C region under the control of native transcriptional
signals both by stably transformed cell lines and by transient
expression. In summary, our studies demonstrate that: (i) C
ORF-specific mRNA can be synthesized under the direction
of subgenomic fragments; (ii) the 5' ends of these transcripts
are heterogeneous; (iii) the sequences immediately upstream
of the C ORF contain promoter activity, which is dependent
on a distant enhancer element; (iv) the synthesis of HBeAg
and HBcAg, under the control of HBV transcriptional sig-
nals, can be accomplished via recombinant molecules; (v)
the intact C ORF can direct the synthesis and secretion of
HBeAg; and (vi) the removal of the precore sequences
results in the loss of HBeAg secretion and the augmentation
of HBcAg synthesis.
TABLE 4. Effect of deletion of precore sequences'
Sampleb Source Anti-HBcc PmNd
pCEN Medium - 7.5
pCEN Medium + 6.4
pCEN Lysate - 2.8
pCEN Lysate + 2.3
pSCAPC Medium - 19.8
pSCA&PC Medium + 1.8
pSCAPC Lysate - 22.6
pSCAPC Lysate + 9.0
a See Table 1, footnote a.
b Hep-G2 cells transiently transfected with the indicated plasmid vector.
I See Table 1, footnote b.
d See Table 3, footnote b.
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In vivo studies have suggested that greater-than-genome-
length transcripts are the mRNA for the core and polymer-
ase genes (6, 10). In our expression systems, however, we
were able to demonstrate that subgenomic fragments are
capable of directing the synthesis of poly(A)+ C-region-
related RNA transcripts. The size of the RNA is consistent
with the use of a modified polyadenylation signal
(AUUAAU) found at nt 2583, which is followed by the
sequence CACUGUAAA at nt 2615. Modifications of the
AAUAAA sequence are used as polyadenylation signals in
about 20% of the known mRNAs (33). The consensus
sequence CAYUGNAAA has been proposed as a secondary
recognition sequence for polyadenylation, involved in small
nuclear ribonucleoprotein binding (2). Further analysis of
this poly(A)+ RNA by S1 nuclease digestion revealed heter-
ogeneous 5' ends mapping before and after the first ATG of
the C ORF.
Our analysis of transcriptional signals upstream of the
C ORF revealed a promoter sequence which is dependent
upon the enhancer sequences located about 350 to 400 bp
upstream. The HBV enhancer element, however, is func-
tional only in human hepatoma cell lines (14, 22). This
explains the difficulty in achieving detectable levels of C
ORF-related expression in other cell lines, as we showed in
NEC-4 and NER-41.
Using the commercially available HBe RIA (Abbott Lab-
oratories) we examined the synthesis of the core and e
antigen polypeptides. The e antigen appeared to be secreted
into the culture medium, and its secretion was abolished by
deleting precore sequences. The 29 amino acids encoded by
the precore sequences showed a high degree of hydropho-
bicity, a feature characteristic of signal peptides (3). The
association of these sequences with HBeAg secretion seems
reasonable in view of the presence of HBeAg in the sera of
infected individuals, and has been suggested by others (J.
Ou, D. Standring, and W. Rutter, personal communication).
Detectable HBcAg synthesis under the transcriptional
control of native regulatory sequences via recombinant
vectors has not been previously achieved in cultured cells.
In our expression system we found that HBcAg synthesis
was accomplished only by the removal of precore se-
quences. Similar results were also found by using the simian
virus 40 late promoter to direct C ORF expression (34). How
this relates to the expression of HBcAg in natural infection is
unclear.
In the transient expression of pSCAPC in Hep-G2 cells,
HBcAg was synthesized in much greater amounts than the e
antigen synthesis observed with pCEN. This dramatic
derepression of HBcAg synthesis suggests that the nucleo-
tide sequences that were deleted (MstI to RsaI, nt 1806 to
1856) are important in the regulation of C ORF-encoded
proteins. This hypothesis is complicated by the failure of
pCMCAT, which contains HBV sequences up to the MstI
site, to direct significant CAT expression, whereas
pCPCAT, in which all the sequences including the two ATGs
are retained, is fully capable of expressing CAT activity.
This suggests that the sequences adjacent to the MstI and
RsaI sites are important components of the regulation of
C-region expression.
A tentative model can be put forward now to account for
our observations and those of others. The C ORF promoter
region controls the expression of a number of mRNAs with
heterogeneous 5' ends. The differential expression of these
mRNAs may account for the different levels of expression of
HBeAg and HBcAg seen in the rat fibroblast and Hep-G2
cell lines. Translational regulation, as well as posttransla-
tional processing, may also be important control mecha-
nisms affecting the levels of HBcAg and HBeAg. It is
apparent that precore sequences contain a strong regulatory
element for the expression of HBeAg and HBcAg in
transfected cells. The exact location and function of this
element is unknown. It should be noted that the second copy
of the direct repeat (31), which may be an important control
element of the HBV genome, is located at map position 1830
and is completely deleted in pSCAPC. Finally, it seems
likely that the sequences between the first two ATGs of the
C ORF code for a signal peptide which controls the secretion
of the HBeAg, since elimination of this sequence abolishes
HBeAg secretion but not its synthesis. Further analyses of
both the transcripts and the polypeptides expressed by the C
ORF are needed to determine the regulatory aspects of
HBcAg and HBeAg synthesis.
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